Common name
pyridine
IUPAC name
pyridine
SMILES
c1cccnc1
Common name
pyridine
IUPAC name
pyridine
SMILES
c1cccnc1
INCHI
InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H
FORMULA
C5H5N
Common name
pyridine
IUPAC name
pyridine
Molecular weight
79.100
clogP
1.626
clogS
-1.146
Frequency
0.0333
HBond Acceptor
1
HBond Donor
0
Total PolarSurface Area
12.89
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01290 | Nicotinamide |
|
Vitamin B Complex; Vitamins; Alimentary Tract and Metabolism; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; | |
| FDBD01336 | Nilotinib |
|
Antineoplastic Agents; Immunosuppressive Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | For the potential treatment of various leukemias, including chronic myeloid leukemia (CML). |
| FDBD01342 | Bepotastine |
|
Mast Cell Stabilizers; | For the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis. |
| FDBD01372 | Abiraterone |
|
Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; Steroid Synthesis Inhibitors; Cytochrome P-450 Enzyme Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. |
| FDBD01433 | Mepyramine |
|
Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Respiratory System; Dermatologicals; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Antihistamines for Topical Use; Antihistamines for Systemic Use; Substituted Ethylene Diamines; Sleep Aids, Pharmaceutical; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Mepyramine is a first generation antihistamine used in treating allergies, ymptomatic relief of hypersensitivity reaction, and in pruritic skin disorders. |
| FDBD01435 | Dabigatran etexilate |
|
Antithrombins; Direct Thrombin Inhibitors; Antithrombotic Agents; Blood and Blood Forming Organs; | Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL . |
| FDBD01438 | Betahistine |
|
Vasodilator Agents; Histamine Agonists; Antiemetics; Nervous System; Antivertigo Preparations; | For the reduction of episodes of vertigo association with Ménière's disease. |
| FDBD01439 | Degarelix |
|
Gonadotropin-releasing hormone antagonist; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; | Degaralix is used for the management of advanced prostate cancer. |
| FDBD01461 | Lornoxicam |
|
Anti-Inflammatory Agents, Non-Steroidal; Musculo-Skeletal System; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory and Antirheumatic Products; Oxicams; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; | For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases. |
| FDBD01481 | Ganirelix |
|
Hormone Antagonists; Pituitary and Hypothalamic Hormones and Analogues; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Anti-Gonadotropin-Releasing Hormones; Hypothalamic Hormones; | For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. |
97 ,
10
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1xh5_ligand_frag_1.mol2 | 1xh5 | 1 | -6.40 | c1ccncc1 | 6 |
| 1xh6_ligand_frag_7.mol2 | 1xh6 | 1 | -6.40 | c1ccncc1 | 6 |
| 1svh_ligand_frag_7.mol2 | 1svh | 1 | -6.39 | c1ccncc1 | 6 |
| 1xh9_ligand_frag_1.mol2 | 1xh9 | 1 | -6.39 | c1ccncc1 | 6 |
| 2gnj_ligand_frag_3.mol2 | 2gnj | 1 | -6.39 | c1ccncc1 | 6 |
| 3dne_ligand_frag_1.mol2 | 3dne | 1 | -6.39 | c1ccncc1 | 6 |
| 1xh4_ligand_frag_1.mol2 | 1xh4 | 1 | -6.38 | c1ccncc1 | 6 |
| 1xh8_ligand_frag_1.mol2 | 1xh8 | 1 | -6.38 | c1ccncc1 | 6 |
645 ,
65
